{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:40:04Z","timestamp":1746340804573,"version":"3.40.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chongqing Health Committee","award":["ZY2021036"],"award-info":[{"award-number":["ZY2021036"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The impact of bevacizumab (an anti-vascular endothelial growth factor therapy) remains uncertain, which has been the focus of studies on the management of ovarian cancer (OC). We performed a protocol for systematic review and meta-analysis to assess the efficacy and safety of bevacizumab combined with chemotherapy in OC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The presentation of methods and results in this systematic review was performed according to the evaluation guidelines for health care interventions provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol. This study will use the Cochrane Library, Web of Science, PubMed, Embase, Allied and Complementary Medicine Database, China Biomedical Literature Database, China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Database, and Ongoing Clinical Trials Database. The risk of bias of included studies is estimated by taking into consideration the characteristics including random sequence generation, allocation concealment, blinding of patients, blinding of outcome assessment, completeness of outcome data, selective reporting, and other bias by Cochrane Collaboration's tool. All analyses were performed with Review Manager (RevMan) software, version 5.3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The results of this systematic review and meta-analysis will be published in a peer-reviewed journal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Bevacizumab combined with chemotherapy may improve progression-free survival and overall survival in patients with OC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028376","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T14:38:18Z","timestamp":1640270298000},"page":"e28376","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Bevacizumab combined with chemotherapy for ovarian cancer"],"prefix":"10.1097","volume":"100","author":[{"given":"Ting","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Chongqing General Hospital, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Zhongxian People's Hospital of Chongqing, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-1251","authenticated-orcid":false,"given":"Liya","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, the Sixth People's Hospital of Chongqing, Chongqing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"m3773","DOI":"10.1136\/bmj.m3773","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"(suppl_8)","key":"R4-20250504","doi-asserted-by":"crossref","first-page":"i61","DOI":"10.1093\/annonc\/mdx443","article-title":"Real-world evidence in the treatment of ovarian cancer","volume":"28","author":"Eisenhauer","year":"2017","journal-title":"Ann Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1570161115666170105124038","article-title":"Vascular endothelial growth factor (vegf) signaling in tumour vascularization: potential and challenges","volume":"15","author":"Siveen","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"R8-20250504","first-page":"w20011","article-title":"Vascular endothelial growth factor biology for regenerative angiogenesis","volume":"149","author":"Uccelli","year":"2019","journal-title":"Swiss Med Wkly"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"02","DOI":"10.1186\/s11658-017-0058-9","article-title":"VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer","volume":"23","author":"Chen","year":"2018","journal-title":"Cell Mol Biol Lett"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2018.03.058","article-title":"Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer","volume":"150","author":"Liu","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future","volume":"27 suppl 1","author":"Monk","year":"2016","journal-title":"Ann Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2015.07.008","article-title":"State of the science: emerging therapeutic strategies for targeting angiogenesis in ovarian cancer","volume":"138","author":"Graybill","year":"2015","journal-title":"Gynecol Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:07:41Z","timestamp":1746338861000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028376"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":17,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028376","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"assertion":[{"value":"2021-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}